Cipla margin falls to 14.60% as costs rise despite weaker revenue
Operating margin declined for a third straight quarter, while net profit fell 55.32% YoY and remained partly supported by other income.
Filed 13 May 2026, 12:36 IST · Cipla Ltd (CIPLA)
Key takeaways
- Costs rose +7.59% YoY while revenue fell -2.80%, reducing operating margin by 8.25 percentage points to 14.60%.
- Consolidated net profit fell -55.32% YoY, with other income contributing 20.10% of pre-tax profit and the tax rate rising 3.74 percentage points.
- Cipla's 14.60% operating margin was 8.78 percentage points below the 23.38% median for 48 reported Healthcare peers.
Price around the results
Q4FY26 profit dropped faster than revenue
Cipla's consolidated revenue declined -2.80% YoY and -7.54% QoQ, but expenses rose +7.59% YoY and fell only -4.01% QoQ. That mismatch cut operating profit by -37.89% YoY and -23.91% QoQ. Management said the company delivered double-digit growth across three segments, while also flagging near-term challenges in North America.
Margin pressure deepened as costs and depreciation rose
Operating margin narrowed 8.25 percentage points YoY and 3.14 percentage points QoQ because costs grew faster than revenue in both comparisons. Depreciation increased +24.03% YoY and +37.57% QoQ, more than offsetting the -6.35% YoY and -6.41% QoQ declines in interest expense. The 22.44% tax rate was 3.74 percentage points higher YoY but 2.04 percentage points lower QoQ.
Three-quarter margin decline leaves Cipla below peers
Operating margin has fallen from 24.97% in Q2FY26 to 17.74% in Q3FY26 and 14.60% in Q4FY26, marking a third consecutive quarterly decline. Q4FY26 margin was 8.78 percentage points below the 23.38% median among 48 Healthcare peers that had reported. Other income was 20.10% of pre-tax profit, so reported earnings included a material non-operating contribution.
Management points to respiratory launches and North America risks
Management said the gVentolin launch is expected in the coming months and that four respiratory pipeline assets are expected to be commercialized in FY27. The company also told analysts that four respiratory assets are planned for filing over the next 24 months, while select peptide and complex generic launches are expected in FY27-FY28. Its presentation flags near-term challenges in North America alongside 17 new launches recorded in FY26.
Initial stock move was ordinary, later gains were larger
The stock rose +2.73% on the results day, close to its historical median absolute post-results move of 3.00%; it had risen after 3 of its last 8 results and fallen after 5. The move extended to +11.17% by the next session and +8.30% after five sessions. Corporate-action overlap means the later response is not a clean results-only reaction.
Q4FY26 at a glance
Consolidated figures as filed with NSE — cross-checked against an independent source.
| Line item | Q4FY26 | Q3FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹6,541 cr | ₹7,074 cr | -7.54% | -2.80% |
| Other income | ₹141 cr | ₹-70 cr | — | -49.54% |
| Expenses | ₹5,586 cr | ₹5,819 cr | -4.01% | +7.59% |
| Operating profit | ₹955 cr | ₹1,255 cr | -23.91% | -37.89% |
| Operating margin (%) | 14.60% | 17.74% | — | — |
| Interest | ₹13 cr | ₹14 cr | -6.41% | -6.35% |
| Depreciation | ₹383 cr | ₹278 cr | +37.57% | +24.03% |
| Profit before tax | ₹699 cr | ₹893 cr | -21.66% | -53.16% |
| Tax | ₹157 cr | ₹219 cr | -28.19% | -43.80% |
| Net profit | ₹543 cr | ₹674 cr | -19.54% | -55.32% |
| EPS (₹) | ₹6.87 | ₹8.37 | -17.92% | -54.59% |
Operating margin of 14.60% compares with a Healthcare sector median of 23.38% across 48 peers that have reported Q4FY26.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | +2.73% | +2.59% |
| Next session | +11.17% | — |
| 5 sessions | +8.30% | +7.10% |
| 15 sessions | +8.23% | — |
| 30 sessions | +11.44% | — |
Volume on the results session was 3.42× its 20-day average.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- Cipla achieved robust double-digit growth across three segments in Q4FY26.
Guidance & outlook
- The gVentolin launch is expected in the coming months.
- Four respiratory pipeline assets are expected to be commercialized in FY27.
- Cipla plans to file four respiratory assets in the next 24 months.
- Select peptide and complex generic launches are expected in FY27-FY28.
- One oligonucleotide and two 505(b)(2) assets are planned for filing over the next 12-18 months.
New products
- Cipla recorded 17 new launches in FY26.
Competition
- Albuterol ranked number one with a 19.6% total market share.
Problems & risks
- North America is facing near-term challenges.
What to watch
- Whether operating margin recovers from 14.60% after its third straight quarterly decline.
- Whether the gVentolin launch reported by management appears in the next-quarter update.
- Whether North America's near-term challenges continue to weigh on consolidated revenue after the -2.80% YoY decline.